Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 5:810:70-82.
doi: 10.1016/j.ejphar.2017.05.064. Epub 2017 Jun 2.

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme

Dimitry A Chistiakov  1 , Ivan V Chekhonin  2 , Vladimir P Chekhonin  3
Affiliations
Review

The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme

Dimitry A Chistiakov et al. Eur J Pharmacol. .

Abstract

In epithelial tumors, the epidermal growth factor receptor (EGFR) controls key signaling pathways responsible for growth, proliferation, migration, and survival of tumor cells. The epidermal growth factor receptor variant III (EGFRvIII) is the most common EGFR mutation that occurs in up to 30% of high-grade gliomas especially glioblastoma multiforme (GBM). EGFRvIII arises from the deletion of exon 2-7 that leads to the formation of the constitutively activated mutant receptor incapable of binding any known ligand. EGFRvIII-expressing cells are resistant to EGFR inhibitors and therefore take advantage in survival. Furthermore, EGFRvIII expression in tumors is often correlates with poor prognosis. Indeed, EGFRvIII targeting is of great therapeutic value in order to inhibit GBM progression and invasion. The presence of the unique glycine site in EGFRvIII provides an option to develop EGFRvIII-specific monoclonal antibodies (MAbs). These antibodies are used for detection of EGFRvIII and immunotherapy. Peptide CDX-110 derived from EGFRvIII has high immunogenicity. This peptide was used for the development of anti-EGFRvIII MAbs with improved specificity to the mutant receptor, EGFRvIII-specific dendritic cell vaccine, and CDX-110-KLH peptide vaccine. These immune reagents were successfully tested in preclinical and clinical studies for GBM treatment.

Keywords: EGFR; EGFRvIII; Glioblastoma; Immunotherapy; Monoclonal antibody; Rindopepimut vaccine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles